Synopsis: Nephrocare Health Services & Park Medi World IPO is expected to list on 17 Dec 2025, with the allotment of shares coming out on 15th Dec 2025. Let’s see how to check the allotment status as well as the financial health of the firm.
Two well-known companies have recently launched their IPO and garnered a huge response, in which Nephrocare Health Services was subscribed by 14.08x, and Park Medi World was subscribed by 8.52x.
Nephrocare Health Services IPO offered shares at a price band set at Rs. 438 to Rs. 460 per share, with a face value of Rs. 2 per and the lot size for an applicant at 32 shares. The company’s book build issue was of Rs. 871.05 crores. The issue is a combination of fresh issue of 0.77 crore shares aggregating to Rs. 353.40 crores and offer for sale of 1.13 crore shares aggregating to Rs. 517.64 crores.
Park Medi World IPO offered shares at a price band set at Rs. 154 to Rs. 162 per share, with a face value of Rs. 2 per and the lot size for an applicant at 92 shares. The company’s book build issue was of Rs. 920.00 crores. The issue is a combination of fresh issue of 4.75 crore shares aggregating to Rs. 770.00 crores and offer for sale of 0.93 crore shares aggregating to Rs. 150.00 crores.
Timeline of the IPO
The Nephrocare Health Services and Park Medi World IPO was opened on December 10, 2025, and closed on December 12, 2025, and the cut-off time for UPI mandate confirmation was set at 5 PM on December 12.
The tentative allotment date is December 15, 2025, followed by the initiation of refunds and credit of shares to Demat accounts on December 16, 2025. The IPO is expected to list on December 17, 2025, on both NSE and BSE.
Steps to check IPO allotment
Both Nephrocare Health Services and Park Medi World IPOs have KFin Technologies Ltd. as the registrar of the issue. Let’s see the steps to check the allotment status.
Step 1: Go to the Registrar website, which is Kfin Technologies Ltd, for this IPO:
https://ipostatus.kfintech.com
Step 2: Select the IPO company name.
Step 3: Enter your PAN/Application/Beneficiary number in the section, and you can view the status of your IPO allotment.
GMP
As of December 15, 2025, the shares of Nephrocare Health IPO in the grey market were trading at an 8.48 percent premium. The shares in the Grey Market traded at Rs. 499. This gives it a premium of Rs. 39 per share over the cap price of Rs. 460.00.
As of December 15, 2025, the shares of Park Medi World IPO in the grey market were trading at a 3.70 percent premium. The shares in the Grey Market traded at Rs. 168. This gives it a premium of Rs. 6 per share over the cap price of Rs. 162.00.
IPO Reservation
Nephrocare Health IPO Reservation
Nephrocare Health IPO offers a total of 1,89,35,819 shares. Out of which 94,26,143 (49.78%) allocated to QIB, 37,68,224 (19.90%) allocated to QIB (Ex- Anchor), 28,27,843 (14.93%) allocated to NII, 65,98,301 (34.85%) allocated to RII and 56,57,919 (29.88%) allocated to Anchor investors.
Park Medi World IPO Reservation
Park Medi World IPO offers a total of 5,67,90,124 shares. Out of which 2,83,95,062 (50.00%) allocated to QIB, 1,13,58,026 (20.00%) allocated to QIB (Ex- Anchor), 85,18,519 (15.00%) allocated to NII, 1,98,76,543 (35.00%) allocated to RII and 1,70,37,036 (30.00%) allocated to Anchor investors.
Objectives of the IPO
Nephrocare Health intends to utilize the net proceeds from its IPO primarily for expanding its operations and strengthening its financial position. The funds will be allocated towards capital expenditure for opening new dialysis clinics in India (Rs. 129.11 crore), pre-paying or repaying certain existing borrowings (Rs. 136.00 crore), and for general corporate purposes to support overall business activities.
Park Medi World plans to utilize the net proceeds from its IPO to strengthen its financial and operational foundation. The funds will be used for repayment or prepayment of certain outstanding borrowings (Rs. 380.00 crore), capital expenditure for developing a new hospital and expanding existing hospitals (Rs. 60.50 crore), purchase of medical equipment (Rs. 27.46 crore), and for unidentified inorganic acquisitions as well as general corporate purposes.
About the company & Financials
Nephrocare Health Services Ltd
Nephrocare Health Services Ltd, Incorporated in 2010, provides end-to-end dialysis care through a wide network of clinics across India and select international markets. The company offers services including diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy.
As of Sep 30, 2025, Nephrocare operated 519 clinics with 51 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 288 cities in 21 States and 4 Union Territories. Approximately 77.53% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions.
Nephrocare Health Services Ltd. has demonstrated steady financial performance in recent years. The company’s total income grew from Rs. 443.26 crore in FY23 to Rs. 574.72 crore in FY24, reaching Rs. 769.92 crore in FY25, with Rs. 483.97 crore recorded for the quarter ended 30 September 2025.
Profit After Tax (PAT) showed improvement, rising from a loss of Rs. 11.79 crore in FY23 to Rs. 35.13 crore in FY24, further increasing to Rs. 67.10 crore in FY25, and Rs. 14.23 crore for the quarter ended 30 September 2025.
Park Medi World Limited
Park Medi World Limited. Incorporated in 2011, it is a private hospital chain in North India, operating 14 multi-super speciality hospitals under the ‘Park’ brand with a total bed capacity of 3,000 as of March 31, 2025. All hospitals are NABH-accredited, with eight also holding NABL accreditation, and are located across Haryana, Delhi, Punjab, and Rajasthan. The network offers over 30 super speciality and speciality services, including internal medicine, neurology, urology, gastroenterology, general surgery, orthopaedics, and oncology.
As of September 30, 2025, the hospitals are equipped with 870 ICU beds, 67 operating theatres, and an oxygen generation plant at each facility to support critical care. The chain’s infrastructure and accreditation standards reflect its focus on delivering comprehensive, high-quality healthcare services across the region.
Park Medi World Limited has demonstrated steady financial performance in recent years. The company’s total income grew from Rs. 1,272.18 crore in FY23 to Rs. 1,263.08 crore in FY24, reaching Rs. 1,425.97 crore in FY25, with Rs. 823.39 crore recorded for the quarter ended 30 September 2025.
Profit After Tax (PAT) showed fluctuations, from Rs. 228.19 crore in FY23 to Rs. 152.01 crore in FY24, further improving to Rs. 213.22 crore in FY25, and Rs. 139.14 crore for the quarter ended 30 September 2025.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
